Other languages Oculis Holding AG

Equities

OCS

CH1242303498

End-of-day quote Nasdaq Other stock markets 03:30:00 05/06/2024 am IST			5-day change	1st Jan Change
11.95 ^USD	+0.84%		+1.62%	+6.41%

30/05	Oculis Holding AG Announces Board and Committee Appointments	CI
30/05	Oculis Holding AG announced a financing transaction	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Oculis Holding AG Announces Board and Committee Appointments	30/05
Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development	10/04
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	08/04
Oculis Holding Files $300 Million Mixed-Securities Shelf Registration	01/04
Oculis Narrows Q4 Loss, Improves Cash Position -- Shares Fall	18/03
Oculis Holding AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Oculis Holding AG Announces Executive Appointments	28/02
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	20/12
Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema	18/12
Oculis Evaluating First Patient in Phase 2b Trial	07/12
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease	07/12
Oculis Says Phase 3 Stage 1 Trial of Diabetic Macular Edema Drug Candidate Met Primary, Secondary Endpoints	10/23/10
Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress	10/23/10
Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema	05/23/05
Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer	11/23/11
Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops	08/23/08
Oculis Holding Prices $40.3 Million Ordinary Stock Offering	01/23/01
Oculis Holding Begins Public Offering of Five Million Shares	30/23/30
Oculis Holding Says its OCS-01 Diabetic Macular Edema Drug Candidate Met Efficacy Primary Endpoint in Late-Stage Study	22/23/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Oculis Holding AG

Equities

OCS

CH1242303498

Other languages

Filters